Ministry of high education and scientific research
Middle Euphrates University / Kufa Institute
Community Health Department
المجتمع

وزارة التعليم العالي والبحث العلمي
جامعة الفرات الاوسط /المعهد التقني كوفة
قسم تقنيات صحة

مرض سرطان الرئة

LUNG CANCER

بحث مقدم الى رئاسة قسم صحة المجتمع جامعة الفرات الاوسط كجزء من متطلبات نيل شهادة الدبلوم

لعام 2024-2025

تحت اشراف:

م. د. نور ابراهيم عبد الزهره شبر

اعداد الطلبة:

منتظر نعمه سلمان – محمد ناجح جهادي – تبارك ياس– آيات وارد يوسف
محمد هادي– مهدي صالح هادي– مريم حامد– ميعاد جمال
نور الهدى جليل– نور الهدى سهام– احمد قائد– رداد ظاهر
احمد حبيب ظاهر– السجاد ثائر– مصطفى كاظم

2025 A.D **1446A.H**

بسم الله الرحمن الرحيم

((وَلَا تَقْفُ مَا لَيْسَ لَكَ بِهِ عِلْمٌ ۚ إِنَّ السَّمْعَ وَالْبَصَرَ وَالْفُؤَادَ كُلُّ أولئك كَانَ عَنْهُ مَسْئُولًا))

صدق الله العلي العظيم

أية (36) من سورة الإسراء

الإهداء

إلى ذلك الجبل الشامخ أمام الأعداء..

إلى الرقة والحنان عند سيد الأوصياء...

إلى الزهرة النقية بين يدي رب السماء.....

إلى الراضية المرضية الحوراء الأنسية فاطمة الزهراء...

الباحثون

شُكْرٌ وامتنان

الحمد لله تعالى خالق الأرض والنبات، وجاعل الموت والحياة، والشكر له دائماً وأبداً على جميع النعمات. والصلاة والسلام على سيد الرسل، وخيرة الأنبياء الأكمل، السراج المنير، محمد بن عبد الله وآلة الطيبين الطاهرين.

أما بعد:

انطلاقا من الجانب الأخلاقي الفطري، وقول الإمام علي بن الحسين "عليه السلام: (أما حقُّ ذي المعروف عليك فأن تشكره وتذكر معروفة وتكسبه المقالة الحسنة، وتخلص له الدعاء فيما بينك وبين الله عزّ وجلَّ، فإذا فعلت ذلك كنت قد شكرته سرّاً وعلانيةً، ثم إن قدرت على مكافأته يوماً كافيته) (الخصال: ٥٦٨).
ويقول (عليه السلام): (أَشْكَركم لله أَشْكَركم للناس) (كنز العمال/6478).

نتقدم بالشكر الجزيل، والثناء الجميل، إلى أستاذتنا الحبيبة المشرفة الدكتورة (م. د. نور ابراهيم شبر) ، التي بذلت من جهودها أقصاها ، ومن قدراتها أمداها ، ومن عطاياها أجزاها .

كما ونشكر جميع كادر قسم صحة المجتمع المحترمون، لما يملكونه من ثمار الخلق اليانعة، وازهار الود المتفتحة، وأوراق الحب المتواضعة، وسيقان الأبوة الحنونة، وجذور العلم الراسخة.

الباحثون

إقرار المشرفة

أشهد أن إعداد مشروع التخرج الموسوم:(*سرطان الرئة*) للطلبة:

- منتظر نعمه سلمان **** رداد ظاهر حبيب
- نور الهدى سلام **** نور الهدى جليل
- محمد هادي حسين **** محمد ناجح جهادي
- مهدي صالح هادي **** مريم حامد كاظم
- تبارك ياس مسلم **** احمد حبيب ظاهر
- مصطفى كاظم **** السجاد ثائر حسين

- ميعاد جمال كشيش**** آيات وارد يوسف
- احمد قائد ناظم

الأشراف: م. د. نور ابراهيم عبد الزهره شبر

التوقيع:

التأريخ: / /2025 م

توصية رئيس القسم

بناءً على توصية م. د. نور ابراهيم عبد الزهره شبر **أُحيل مشروع التخرج هذا إلى لجنة المناقشة.**

رئيس القسم: د. احمد

التأريخ: / /٢٠٢5 م.

التوقيع:

Abstract

Worldwide over 1 million people die due to lung cancer each year. It is estimated that cigarette smoking explains almost 90% of lung cancer risk in men and 70 to 80% in women. Clinically evident lung cancers have multiple genetic and epigenetic abnormalities. These abnormalities may result in activation of oncogenes and inactivation of tumor-suppressor genes. Chronic inflammation, which is known to promote cancer, may result both from smoking and from genetic abnormalities. These mediators in turn may be responsible for increased macrophage recruitment, delayed neutrophil clearance, and increase in reactive oxygen species (ROS). Thus, the pulmonary environment presents a unique milieu in which lung carcinogenesis proceeds in complicity with the host cellular network. The pulmonary diseases that are associated with the greatest risk for lung cancer are characterized by abundant and deregulated inflammation. Pulmonary disorders such as chronic obstructive pulmonary disease (COPD)/emphysema are characterized by profound abnormalities in inflammatory and fibrotic pathways. The cytokines and growth factors aberrantly produced in COPD and the developing tumor microenvironment have been found to have deleterious properties that simultaneously pave the way for both epithelial–mesenchymal transition (EMT) and destruction of specific host cell–mediated immune responses. Full definition of these pathways will afford the

opportunity to intervene in specific inflammatory events mediating lung tumorigenesis and resistance to therapy.

Keywords: smoking, inflammation, lung cancer, COPD; EMT

Lung cancer is the leading cause of cancer death, both in the United States and worldwide. It is estimated that lung cancer will cause over 160,000 deaths in the United States in 2007, and greater than one million deaths worldwide. The most important risk factor for lung cancer is tobacco smoking, and the data supporting this relationship are compelling (1). Compared with nonsmokers, smokers have as much as a 30-fold increased risk of developing cancer (1–3). Thirty-one percent and 26% of all cancer deaths in men and women, respectively, result from lung cancer in the United States. Overall 5-year survival is only 15%, and 1-year survival is approximately 42%. In total, lung cancer is responsible for more deaths than prostate, colon, pancreas, and breast cancers combined. Woloshin and coworkers have recently framed the health risks due to smoking status in a different context (4). For men age 60 and above who currently smoke, the chance of dying from lung cancer is of the same order of magnitude as the chance of dying from heart disease. After age 50, it is 10 times greater than the chance of dying from prostate or colon cancer. For women who currently smoke, the chance of death due to lung cancer exceeds the chance of dying from breast cancer from age 40 onward (4). The tobacco smoking–induced inflammatory response yields an array of deregulated cells, cytokines, and growth factors that are conducive to the development of both chronic obstructive pulmonary disease (COPD) and lung cancer. Inflammation has been suggested to promote lung cancer via several possible pathways. For example, inflammatory cell–derived reactive nitrogen or oxygen species may bind to DNA and thus lead to genomic alterations (5, 6).

Thus, pulmonary inflammation could play a role in cancer initiation or promotion. The pulmonary environment of COPD, including ongoing tissue repair with enhanced cellular proliferation, could be conducive to both DNA mutation and angiogenesis (6). In addition, the proinflammatory cytokines released in this milieu elevate epithelial apoptosis resistance.

SMOKING, INFLAMMATION, AND LUNG CANCER

Lung cancer evolves as a result of a series of mutational events that have been studied in detail by numerous investigators (7). However, the molecular pathogenesis of lung cancer remains incompletely defined. Because inflammation appears to play an important role in the pathogenesis of lung cancer, a thorough understanding of lung cancer pathogenesis requires consideration of the tumor microenvironment (TME) and the inflammatory pathways operative in carcinogenesis (8).

The tobacco-induced pulmonary cellular network presents a unique environment in which carcinogenesis proceeds in complicity with surrounding lung inflammatory, structural, and stromal cells. The pulmonary diseases that are associated with the greatest risk for lung cancer are characterized by abundant and deregulated inflammation (9–11). Pulmonary disorders such as COPD are characterized by profound abnormalities in inflammatory pathways (12–14).

For example, among the cytokines, growth factors, and mediators released in these lung diseases and the developing TME, interleukin (IL)-1β, prostaglandin (PG)E_2, and transforming growth factor (TGF)-β have been found to have deleterious properties that simultaneously pave the way for both epithelial–mesenchymal transition (EMT) and destruction of specific host cell–mediated immune responses against tumor antigens (15–19).

The commonalities in smoking, COPD, and lung cancer begin with the profound alterations induced by cigarette smoke, which contains known carcinogens as well as high levels of reactive oxygen species (ROS). The ready induction of ROS after tobacco smoke exposure leads to impairment of epithelial and endothelial cell function as well as inflammation. The ongoing inflammatory processes in COPD may be persistent even after smoking cessation and have been quantified and related to disease progression (20). As COPD progresses, the percentage of the airways that contain macrophages, neutrophils, T cells, B cells, and lymphoid aggregates containing follicles increases (20).

THE FIELD CANCERIZATION EFFECT

Beginning with the groundbreaking investigations of Auerbach and colleagues (21), an extensive literature documents that tobacco smokers' respiratory epithelium often contains multifocal premalignant lesions that can occur

throughout the bronchial tree. These findings have been referred to as the field cancerization effect, and implicate the capacity of tobacco carcinogens to mutagenize the respiratory epithelium extensively (22). In analyzing premalignant and malignant epithelium from patients with squamous cell carcinoma, Wistuba and coworkers found multiple, sequentially occurring allele-specific chromosomal deletions (loss of heterozygosity) in widely dispersed, apparently clonally independent foci, early in the multistage pathogenesis of lung squamous cell carcinoma (23–25). The bronchial epithelium in current and former smokers also demonstrates multiple foci of genetic changes, as seen in patients with lung cancers. Importantly, these changes may persist for many years after smoking cessation (26–28). These persistent abnormalities serve as a driving force for increased risk in a growing population; there are more than 45 million former smokers in the United States, and the majority of new lung cancer diagnoses now occurs in former smokers.

In addition to premalignant lesions that are visible by histologic inspection, studies document that smoking induces field effect abnormalities even in histologically normal lung epithelium (26, 29, 30). High-density gene expression arrays have been used to define genes in human airway epithelial cells that are altered by cigarette smoking (31–35). The data obtained in these studies are expected to provide insights into lung cancer risk in smokers, with or without COPD. Spira and colleagues recently reported that gene expression profiles in histologically normal large airway epithelial cells could serve as a biomarker for the presence of lung cancer (36). These findings provide a strong case for the presence of a diffuse airway response to tobacco smoke that is not necessarily demonstrable by conventional histologic assessments. Because the airway gene expression profiles provide important information about the possible development of lung cancer that is not adequately predicted by clinically defined risk alone, Beane and coworkers have recently proposed a clinicogenomic model that has a higher prediction accuracy (37)

.

The tobacco smoking–induced changes in gene expression and cellular functions are not confined to the pulmonary airway epithelium but have also been reported in

the nasal and buccal epithelium (38, 39), alveolar macrophages (40, 41), and peripheral blood (42). These findings are consistent with the previously presented hypotheses regarding the systemic inflammatory process operative in patients with COPD as well as in those with lung cancer.

EPITHELIAL–MESENCHYMAL TRANSITION

EMT has been initially described as a process in embryonic development. EMT is composed of a developmental shift from a polarized, epithelial phenotype to a highly motile fibroblastoid or mesenchymal phenotype (43). In addition to embryonic development, EMT has been implicated in chronic inflammation, fibrosis, and cancer development (44–47). In normal development, EMT is a tightly regulated process (47). In contrast, in cancer development and progression, EMT is unregulated, with selective elements of the process amplified while other aspects are circumvented (48)

CONCLUSIONS

Lung cancer is often intimately linked to tobacco smoking and inflammation. The investigation of these relationships will lead to a more complete picture of the pulmonary environment at risk for the development of lung cancer. New investigations will revisit the original findings of Auerbach and coworkers with the

application of the powerful tools of current genomics, proteomics, and imaging. The refined definitions of pulmonary inflammation and pre-malignancy will afford new opportunities for advances in risk assessment and prevention.

References

- 1.Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: geographical distribution and secular trends. *J Thorac Oncol* 2008;3:819–831. [DOI] [PubMed] [Google Scholar]
- 2.Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. *Lung Cancer* 2004;45:S3–S9. [DOI] [PubMed] [Google Scholar]
- 3.Proctor RN. Tobacco and the global lung cancer epidemic. *Nat Rev Cancer* 2001;1:82–86. [DOI] [PubMed] [Google Scholar]
- 4.Woloshin S, Schwartz LM, Welch HG. The risk of death by age, sex, and smoking status in the United States: putting health risks in context. *J Natl Cancer Inst* 2008;100:845–853. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. *Blood* 1990;76:655–663. [PubMed] [Google Scholar]

6.Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. *Expert Rev Anticancer Ther* 2008;8:605–615. [DOI] [PubMed] [Google Scholar]

7.Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. *J Thorac Oncol* 2007;2:327–343. [DOI] [PubMed] [Google Scholar]

8.Prendergast GC. Inflammatory mediators in cancer etiology and targets for therapy and prevention. *Cancer Reviews Online* 2008;9:17–18. [Google Scholar]

9.Taraseviciene-Stewart L, Voelkel NF. Molecular pathogenesis of emphysema. *J Clin Invest* 2008;118:394–402. [DOI] [PMC free article] [PubMed] [Google Scholar]

10.O'Donnell R, Breen D, Wilson S, Djukanovic R. Inflammatory cells in the airways in COPD. *Thorax* 2006;61:448–454. [DOI] [PMC free article] [PubMed] [Google Scholar]

11.Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity: a common inflammatory phenotype? *Respir Res* 2006;7:70. [DOI] [PMC free article] [PubMed] [Google Scholar]

12.Reynolds PR, Cosio MG, Hoidal JR. Cigarette smoke-induced Egr-1 upregulates proinflammatory cytokines in pulmonary epithelial cells. *Am J Respir Cell Mol Biol* 2006;35:314–319. [DOI] [PMC free article] [PubMed] [Google Scholar]

13.Smith CJ, Perfetti TA, King JA. Perspectives on pulmonary inflammation and lung cancer risk in cigarette smokers. *Inhal Toxicol* 2006;18:667–677. [DOI] [PubMed] [Google Scholar]

14.Kim V, Rogers TJ, Criner GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2008;5:478–485. [DOI] [PMC free article] [PubMed] [Google Scholar]

15.Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC, *et al.* Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. *Cancer Res* 2006;66:5338–5345. [DOI] [PubMed] [Google Scholar]

16.Charuworn B, Dohadwala M, Krysan K, Sharma S, Escuadro B, Dubinett SM. Inflammation-mediated promotion of EMT in NSCLC: IL-1b mediates a MEK/Erk- and JNK/SAPK-dependent downregulation of E-cadherin [abstract]. *Proc Am Thorac Soc* 2006;3:D96 [Google Scholar]

17.Baratelli F, Lin Y, Zhu L, Yang SC, Heuzé-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S, Dubinett SM. Prostaglandin E_2 induces *FOXP3* gene expression and T regulatory cell function in human $CD4^+$ T cells. *J Immunol* 2005;175:1483–1490. [DOI] [PubMed] [Google Scholar]

18.Keshamouni VG, Michailidis G, Grasso CS, Anthwal S, Strahler JR, Walker A, Arenberg DA, Reddy RC, Akulapalli S, Thannickal VJ, *et al.* Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. *J Proteome Res* 2006;5:1143–1154. [DOI] [PubMed] [Google Scholar]

19.Leng Q, Bentwich Z, Borkow G. Increased TGF-β, Cbl-b and CTLA-4 levels and immunosuppression in association with chronic immune activation. *Int Immunol* 2006;18:637–644. [DOI] [PubMed] [Google Scholar]

20.Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, *et al.* The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med* 2004;350:2645–2653. [DOI] [PubMed] [Google Scholar]

21.Auerbach O, Stout AP, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. *N Engl J Med* 1961;265:253–267. [DOI] [PubMed] [Google Scholar]

22.Wistuba II. Genetics of preneoplasia: lessons from lung cancer. *Curr Mol Med* 2007;7:3–14. [DOI] [PubMed] [Google Scholar]

23.Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, Gazdar AF. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. *Oncogene* 1999;18:643–650. [DOI] [PubMed] [Google Scholar]

24.Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon JW III, Garner HR, McKay B, Latif F, *et al.* High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. *Cancer Res* 2000;60:1949–1960. [PubMed] [Google Scholar]

25.Wistuba II, Berry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S, Mackay B, Minna JD, Gazdar AF. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. *Clin Cancer Res* 2000;6:2604–2610. [PMC free article] [PubMed] [Google Scholar]

26.Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, Samet JM, Srivastava S, Minna JD, Gazdar AF. Molecular damage in the bronchial epithelium of current and former smokers. *J Natl Cancer Inst* 1997;89:1366–1373. [DOI] [PMC free article] [PubMed] [Google Scholar]

27.Franklin WA, Gazdar AF, Haney J, Wistuba II, La Rosa FG, Kennedy T, Ritchey DM, Miller YE. Widely dispersed p53 mutation in respiratory epithelium: a novel mechanism for field carcinogenesis. *J Clin Invest* 1997;100:2133–2137. [DOI] [PMC free article] [PubMed] [Google Scholar]

28.Yashima K, Litzky LA, Kaiser L, Rogers T, Lam S, Wistuba II, Milchgrub S, Srivastava S, Piatyszek MA, Shay JW, *et al.* Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. *Cancer Res* 1997;57:2373–2377. [PubMed] [Google Scholar]

29.Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, Ro JY, Broxson A, Yu R, Morice RC, *et al.* Clonal genetic alterations in the lungs of current and former smokers. *J Natl Cancer Inst* 1997;89:857–862. [DOI] [PubMed] [Google Scholar]

30.Park IW, Wistuba II, Maitra A, Milchgrub S, Virmani AK, Minna JD, Gazdar AF. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. *J Natl Cancer Inst* 1999;91:1863–1868. [DOI] [PubMed] [Google Scholar]

31.Spira A, Beane J, Shah V, Liu G, Schembri F, Yang X, Palma J, Brody JS. Effects of cigarette smoke on the human airway epithelial cell transcriptome. *Proc Natl Acad Sci USA* 2004;101:10143–10148. [DOI] [PMC free article] [PubMed] [Google Scholar]

32.Ammous Z, Hackett NR, Butler MW, Raman T, Dolgalev I, O'Connor TP, Harvey BG, Crystal RG. Variability in small airway epithelial gene expression among normal smokers. *Chest* 2008;133:1344–1353. [DOI] [PMC free article] [PubMed] [Google Scholar]

33.Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, *et al.* Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. *PLoS ONE* 2008;3:e1651. [DOI] [PMC free article] [PubMed] [Google Scholar]

34.Wang IM, Stepaniants S, Boie Y, Mortimer JR, Kennedy B, Elliott M, Hayashi S, Loy L, Coulter S, Cervino S, *et al.* Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. *Am J Respir Crit Care Med* 2008;177:402–411. [DOI] [PubMed] [Google Scholar]

35.Choi IG, Kwon J, Kim SH. Local feature frequency profile: a method to measure structural similarity in proteins. *Proc Natl Acad Sci USA* 2004;101:3797–3802. [DOI] [PMC free article] [PubMed] [Google Scholar]

36.Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, Gilman S, Dumas YM, Calner P, Sebastiani P, *et al.* Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. *Nat Med* 2007;13:361–366. [DOI] [PubMed] [Google Scholar]

37.Beane J, Sebastiani P, Whitfield TH, Steiling K, Dumas YM, Lenburg ME, Spira A. A prediction model for lung cancer diagnosis that integrates genomic and clinical features. *Cancer Prevention Research* 2008;1:56–64. [DOI] [PMC free article] [PubMed] [Google Scholar]

38.Sridhar S, Schembri F, Zeskind J, Shah V, Gustafson AM, Steiling K, Liu G, Dumas YM, Zhang X, Brody JS, *et al.* Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. *BMC Genomics* 2008;9:259. [DOI] [PMC free article] [PubMed] [Google Scholar]

39.Sidransky D. The oral cavity as a molecular mirror of lung carcinogenesis. *Cancer Prevention Research* 2008;1:12–14. [DOI] [PMC free article] [PubMed] [Google Scholar]

40.Stearman RS, Dwyer-Nield L, Grady MC, Malkinson AM, Geraci MW. A macrophage gene expression signature defines a field effect in the lung tumor microenvironment. *Cancer Res* 2008;68:34–43. [DOI] [PubMed] [Google Scholar]

41.Hodge S, Hodge G, Ahern J, Jersmann H, Holmes M, Reynolds PN. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* 2007;37:748–755. [DOI] [PubMed] [Google Scholar]

42.Charles PC, Alder BD, Hilliard EG, Schisler JC, Lineberger RE, Parker JS, Mapara S, Wu SS, Portbury A, Patterson C, *et al.* Tobacco use induces anti-apoptotic, proliferative patterns of gene expression in circulating leukocytes of Caucasian males. *BMC Med Genomics* 2008;1:38. [DOI] [PMC free article] [PubMed] [Google Scholar]

43.Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. *Curr Opin Cell Biol* 2005;17:548–558. [DOI] [PubMed] [Google Scholar]

44.Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H, Mikulits W. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. *Mutat Res* 2004;566:9–20. [DOI] [PubMed] [Google Scholar]

45.Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. *J Clin Invest* 2003;112:1776–1784. [DOI] [PMC free article] [PubMed] [Google Scholar]

46.Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. *Nat Rev Mol Cell Biol* 2003;4:657–665. [DOI] [PubMed] [Google Scholar]

47.Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. *Curr Opin Cell Biol* 2003;15:740–746. [DOI] [PubMed] [Google Scholar]

48.Dasari V, Gallup M, Lemjabbar H, Maltseva I, McNamara N. Epithelial-mesenchymal transition in lung cancer: is tobacco the “smoking gun”? *Am J Respir Cell Mol Biol* 2006;35:3–9. [DOI] [PubMed] [Google Scholar]